Jay Barth Sells 30,000 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD) insider Jay Barth sold 30,000 shares of the stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $15.05, for a total value of $451,500.00. Following the transaction, the insider now owns 193,204 shares in the company, valued at $2,907,720.20. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Jay Barth also recently made the following trade(s):

  • On Thursday, July 9th, Jay Barth sold 44,447 shares of Amicus Therapeutics stock. The stock was sold at an average price of $15.92, for a total value of $707,596.24.
  • On Tuesday, July 7th, Jay Barth sold 178,988 shares of Amicus Therapeutics stock. The stock was sold at an average price of $15.90, for a total value of $2,845,909.20.
  • On Monday, June 29th, Jay Barth sold 30,000 shares of Amicus Therapeutics stock. The stock was sold at an average price of $15.51, for a total value of $465,300.00.
  • On Wednesday, June 17th, Jay Barth sold 1,904 shares of Amicus Therapeutics stock. The shares were sold at an average price of $13.47, for a total value of $25,646.88.

NASDAQ FOLD opened at $14.45 on Friday. The company has a quick ratio of 4.31, a current ratio of 4.45 and a debt-to-equity ratio of 0.50. Amicus Therapeutics, Inc. has a twelve month low of $6.25 and a twelve month high of $16.13. The firm has a market capitalization of $3.78 billion, a PE ratio of -11.12 and a beta of 1.35. The stock’s 50 day moving average is $14.69 and its 200 day moving average is $11.58.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.07). The business had revenue of $60.53 million for the quarter, compared to the consensus estimate of $57.21 million. Amicus Therapeutics had a negative net margin of 155.73% and a negative return on equity of 63.24%. On average, research analysts anticipate that Amicus Therapeutics, Inc. will post -1.08 earnings per share for the current year.

A number of research firms recently commented on FOLD. BidaskClub raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, June 30th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Amicus Therapeutics in a research report on Tuesday, June 16th. Zacks Investment Research lowered Amicus Therapeutics from a “hold” rating to a “sell” rating and set a $16.00 target price for the company. in a research report on Wednesday, July 22nd. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Amicus Therapeutics in a research report on Monday, June 8th. Finally, SVB Leerink reaffirmed a “market perform” rating and set a $19.00 target price on shares of Amicus Therapeutics in a research report on Tuesday, May 19th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company’s stock. Amicus Therapeutics currently has a consensus rating of “Buy” and an average price target of $19.83.

A number of institutional investors have recently made changes to their positions in FOLD. BlackRock Inc. lifted its stake in shares of Amicus Therapeutics by 1.8% in the 1st quarter. BlackRock Inc. now owns 21,239,016 shares of the biopharmaceutical company’s stock valued at $196,248,000 after purchasing an additional 382,909 shares during the last quarter. Janus Henderson Group PLC increased its holdings in shares of Amicus Therapeutics by 8.1% in the 1st quarter. Janus Henderson Group PLC now owns 11,625,924 shares of the biopharmaceutical company’s stock valued at $107,423,000 after acquiring an additional 867,308 shares during the period. State Street Corp increased its holdings in shares of Amicus Therapeutics by 1.2% in the 1st quarter. State Street Corp now owns 11,129,151 shares of the biopharmaceutical company’s stock valued at $102,833,000 after acquiring an additional 132,427 shares during the period. Nuveen Asset Management LLC boosted its position in shares of Amicus Therapeutics by 92.8% in the 4th quarter. Nuveen Asset Management LLC now owns 4,154,771 shares of the biopharmaceutical company’s stock worth $40,468,000 after purchasing an additional 2,000,176 shares in the last quarter. Finally, Deutsche Bank AG lifted its position in Amicus Therapeutics by 153.1% during the 1st quarter. Deutsche Bank AG now owns 4,121,255 shares of the biopharmaceutical company’s stock worth $38,080,000 after acquiring an additional 2,492,623 shares during the period.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.

Further Reading: How does a reverse stock split work?

Insider Buying and Selling by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.